Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RadioTherapeutics' RF 2000

This article was originally published in The Gray Sheet

Executive Summary

Radiofrequency ablation system is cleared by FDA for treatment of nonresectable liver lesions April 7 through the agency's real-time 510(k) review process. The system initially was approved in 1997 for the general indication of soft tissue necrosis. FDA had cited the company in a May 14, 1998 warning letter for stating in a press release that clinical studies of the product demonstrated "its potential to address the significant need for an alternative or complementary treatment for liver tumors that cannot be removed surgically." Boston Scientific distributes the system in the U.S. for radiological applications. RadioTherapeutics will promote the new indication. The device is targeted at the 90% of the roughly 135,000 patients diagnosed with primary or metastatic liver tumors in the U.S. annually who are not candidates for surgery. The company estimates the worldwide patient population at 2 mil., due in large part to the prevalence of hepatitis C infection in Asia
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013226

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel